In the LEADER trial (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results), researchers found that liraglutide reduced the risk of cardiovascular events in diabetic patients, including heart attack, stroke, and cardiovascular death, by 13% compared to placebo
Chronic administration of semaglutide (dose = 0.9 mg/kg) in the research sample contributed to a significant reduction in the concentration of the above proteins associated with inflammation
GLP-1s offer new revenue opportunities for digital health players It's not hard to see why digital health companies are going all-in on the GLP-1 boom
Start with a 0.5-1% concentration serum applied once daily to a clean, dry scalp in the area(s) where youre experiencing thinning
Christensen J, Grnborg TK, Srensen MJ, et al